Los Angeles Times Columnist: Stem Cell Agency Still Saddled with Conflict of Interest Problems
The governing board of the $3 billion California stem cell agency will remain dominated by “special interests” even with the adoption of a plan last week responding to the far-reaching recommendations of a blue-ribbon Institute of Medicine (IOM) study, a columnist for the Los Angeles Times said today.
Michael Hiltzik, Pulitzer Prize winning writer and au…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.